Abstract 130P
Background
At the population level, it is useful to estimate the liver cancer risk based on lifestyle factors and regular biomarkers to encourage high-risk people to be screened. Therefore, we conducted the current study to develop a prediction model for the stratification of liver cancer risk among the general population in China.
Methods
112 440 subjects aged 20-80 years from Kailuan Cohort were included in the current study. A total of 326 incident primary liver cancer occurred during 913 078.51 person-years of follow-up. We used the Cox proportional hazards regression model to obtain coefficients for each predictor in the 8-year prediction models among a random two thirds of participants. The prediction models were validated in the remaining one third of participants. Hosmer-Lemeshow’s statistic and Harrell’s C-index were used to evaluate calibration and discrimination, respectively.
Results
A full prediction model that comprised of nine predictors, including age, sex, smoking pack-years, alcohol drinking, tea consumption, diabetes and fasting blood glucose (FBG) level, total cholesterol (TC), alanine aminotransferase (ALT), and hepatitis B virus surface antigen (HBsAg), was derived. The model showed good calibration (χ2=3.57, P = 0.89) and discrimination (Harrell’s C-index=0.85; 95% confidence interval [CI]: 0.81, 0.88) in the validation data set.
Conclusions
A practical liver prediction model based on accessible indicators combined with lifestyle factors, regular blood biomarkers, and hepatitis virus status was developed, which allows to stratify the risk of liver cancer among the general population. Because the factors in this model are able to be acquired from questionnaire and blood detection, it has great potential to be translated into practical use for public health.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Key R& D Program.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
314P - An EGF motif of Del1 inhibits efficient angiogenesis and suppresses tumour growth in vivo
Presenter: Hisataka Kitano
Session: Poster display session
Resources:
Abstract
315P - Inhibition of JAK1 sensitizes human head and neck cancer cells to cetuximab
Presenter: James Bonner
Session: Poster display session
Resources:
Abstract
316TiP - Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
Presenter: Ezra Cohen
Session: Poster display session
Resources:
Abstract
322P - Three-year overall survival update from the PACIFIC trial
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract
323P - Novel tumour mutation score versus tumour mutation burden in predicting survival after immunotherapy in pan-cancer from MSK-IMPACT cohort
Presenter: Yuan Li
Session: Poster display session
Resources:
Abstract
324P - A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy
Presenter: Tsu Yi Chao
Session: Poster display session
Resources:
Abstract
325P - Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
Presenter: Lawrence Wong
Session: Poster display session
Resources:
Abstract
326P - Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies
Presenter: Esdy Rozali
Session: Poster display session
Resources:
Abstract
327P - Neoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution
Presenter: Xiaolong Liu
Session: Poster display session
Resources:
Abstract
328P - A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors
Presenter: Fumiko Hayashi
Session: Poster display session
Resources:
Abstract